Inhibitory Effect of Sophorolipid on Candida albicans Biofilm Formation and Hyphal Growth

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Haque, Farazul ^a   Alfatah, Md ^a   Ganesan, K ^a   Bhattacharyya, Mani Shankar ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALS1 PROTEIN, CANDIDA ALBICANS; ALS3 PROTEIN, CANDIDA ALBICANS; AMPHOTERICIN B; ANTIFUNGAL AGENT; ASPARTIC PROTEINASE; DRUG COMBINATION; ECE1 PROTEIN, CANDIDA ALBICANS; FLUCONAZOLE; FUNGAL PROTEIN; GLYCOLIPID; HWP1 PROTEIN, CANDIDA ALBICANS; MEMBRANE PROTEIN; SAP4 PROTEIN, CANDIDA ALBICANS; SURFACTANT;

ANTAGONISTS AND INHIBITORS; BIOFILM; BUDDING YEAST; CANDIDA ALBICANS; CHEMISTRY; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; FUNGUS HYPHAE; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; ULTRASTRUCTURE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPARTIC ACID ENDOPEPTIDASES; BIOFILMS; CANDIDA ALBICANS; DRUG COMBINATIONS; DRUG SYNERGISM; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; GLYCOLIPIDS; HYPHAE; MEMBRANE GLYCOPROTEINS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; SACCHAROMYCETALES; SURFACE-ACTIVE AGENTS;

EID: 84962856974     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23575     Document Type: Article

References (58)

1. Pfaller, M. et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn Microbiol Infect Dis 74, 323-31 (2012).
2. Wenzel, R. P., Gennings, C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially highrisk patients to determine prevention strategies. Clin Infect Dis 41 Suppl 6, S389-93 (2005).
3. Miceli, M. H., Diaz, J. A., Lee, S. A. Emerging opportunistic yeast infections. Lancet Infect Dis 11, 142-51 (2011).
4. Papon, N., Courdavault, V., Clastre, M., Bennett, R. J. Emerging and emerged pathogenic Candida species: beyond the Candida albicans paradigm. PLoS Pathog 9, e1003550 (2013).
5. Silva, S. et al. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev 36, 288-305 (2012).
6. Chandra, J. et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183, 5385-94 (2001).
7. Douglas, L. J. Medical importance of biofilms in Candida infections. Rev Iberoam Micol 19, 139-43 (2002).
8. Sardi, J. C., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M., Mendes Giannini, M. J. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 62, 10-24 (2013).
9. Andes, D. R. et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54, 1110-22 (2012).
10. Pfaller, M. A., Diekema, D. J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20, 133-63 (2007).
11. Baillie, G. S., Douglas, L. J. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 46, 397-403 (2000).
12. Finkel, J. S., Mitchell, A. P. Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 9, 109-18 (2011).
13. Finkel, J. S. et al. Portrait of Candida albicans adherence regulators. PLoS Pathog 8, e1002525 (2012).
14. Ramage, G., Saville, S. P., Thomas, D. P., Lopez-Ribot, J. L. Candida biofilms: an update. Eukaryot Cell 4, 633-8 (2005).
15. Taff, H. T., Mitchell, K. F., Edward, J. A., Andes, D. R. Mechanisms of Candida biofilm drug resistance. Future Microbiol 8, 1325-37 (2013).
16. Mukherjee, P. K., Chandra, J. Candida biofilm resistance. Drug Resist Updat 7, 301-9 (2004).
17. Laniado-Laborin, R., Cabrales-Vargas, M. N. Amphotericin B: side effects and toxicity. Rev Iberoam Micol 26, 223-7 (2009).
18. Sharma, S. et al. Sphingolipid biosynthetic pathway genes FEN1 and SUR4 modulate amphotericin B resistance. Antimicrob Agents Chemother 58, 2409-14 (2014).
19. Nett, J. E. Future directions for anti-biofilm therapeutics targeting Candida. Expert Review of Anti-infective Therapy 12, 375-382 (2014).
20. Janek, T., Lukaszewicz, M., Krasowska, A. Antiadhesive activity of the biosurfactant pseudofactin II secreted by the Arctic bacterium Pseudomonas fluorescens BD5. BMC Microbiol 12, 24 (2012).
21. Luna, J. M. et al. Evaluation antimicrobial and antiadhesive properties of the biosurfactant Lunasan produced by Candida sphaerica UCP 0995. Curr Microbiol 62, 1527-34 (2011).
22. Rivardo, F., Turner, R., Allegrone, G., Ceri, H., Martinotti, M. Anti-adhesion activity of two biosurfactants produced by Bacillus spp. prevents biofilm formation of human bacterial pathogens. Applied microbiology and biotechnology 83, 541-553 (2009).
23. Cortes-Sanchez Ade, J., Hernandez-Sanchez, H., Jaramillo-Flores, M. E. Biological activity of glycolipids produced by microorganisms: new trends and possible therapeutic alternatives. Microbiol Res 168, 22-32 (2013).
24. Price, N. P., Ray, K. J., Vermillion, K. E., Dunlap, C. A., Kurtzman, C. P. Structural characterization of novel sophorolipid biosurfactants from a newly identified species of Candida yeast. Carbohydr Res 348, 33-41 (2012).
25. Rodrigues, L., Banat, I. M., Teixeira, J., Oliveira, R. Biosurfactants: potential applications in medicine. J Antimicrob Chemother 57, 609-18 (2006).
26. Kurtzman, C. P., Price, N. P., Ray, K. J., Kuo, T. M. Production of sophorolipid biosurfactants by multiple species of the Starmerella (Candida) bombicola yeast clade. FEMS Microbiol Lett 311, 140-6 (2010).
27. Joshi-Navare, K., Prabhune, A. A biosurfactant-sophorolipid acts in synergy with antibiotics to enhance their efficiency. Biomed Res Int 2013, 512495 (2013).
28. Van Bogaert, I. N. et al. Microbial production and application of sophorolipids. Appl Microbiol Biotechnol 76, 23-34 (2007).
29. Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., Rex, J. H. Combination antifungal therapy. Antimicrob Agents Chemother 48, 693-715 (2004).
30. CLSI. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, third edition, M27-A3. (2008).
31. Sudbery, P. E. Growth of Candida albicans hyphae. Nature Reviews Microbiology 9, 737-748 (2011).
32. Staniszewska, M., Bondaryk, M., Malewski, T., Schaller, M. The expression of the Candida albicans gene SAP4 during hyphal formation in human serum and in adhesion to monolayer cell culture of colorectal carcinoma Caco-2 (ATCC). Central European Journal of Biology 9, 796-810 (2014).
33. Kuiper, I. et al. Characterization of two Pseudomonas putida lipopeptide biosurfactants, putisolvin I and II, which inhibit biofilm formation and break down existing biofilms. Molecular microbiology 51, 97-113 (2004).
34. Rodrigues, L., Van der Mei, H. C., Teixeira, J., Oliveira, R. Influence of biosurfactants from probiotic bacteria on formation of biofilms on voice prostheses. Applied and environmental microbiology 70, 4408-4410 (2004).
35. Mukherji, R., Prabhune, A. Novel glycolipids synthesized using plant essential oils and their application in quorum sensing inhibition and as antibiofilm agents. ScientificWorldJournal 2014, 890709 (2014).
36. Gudina, E. J., Rangarajan, V., Sen, R., Rodrigues, L. R. Potential therapeutic applications of biosurfactants. Trends in pharmacological sciences 34, 667-675 (2013).
37. Basak, G., Das, D., Das, N. Dual role of acidic diacetate sophorolipid as biostabilizer for ZnO nanoparticle synthesis and biofunctionalizing agent against Salmonella enterica and Candida albicans. J Microbiol Biotechnol 24, 87-96 (2014).
38. Berman, J., Sudbery, P. E. Candida albicans: a molecular revolution built on lessons from budding yeast. Nature Reviews Genetics 3, 918-932 (2002).
39. Nobile, C. J., Nett, J. E., Andes, D. R., Mitchell, A. P. Function of Candida albicans adhesin Hwp1 in biofilm formation. Eukaryotic Cell 5, 1604-1610 (2006).
40. Nobile, C. J. et al. Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS pathogens 2, e63 (2006).
41. Lu, Y., Su, C., Wang, A., Liu, H. Hyphal development in Candida albicans requires two temporally linked changes in promoter chromatin for initiation and maintenance. PLoS Biol 9, e1001105 (2011).
42. Vediyappan, G., Dumontet, V., Pelissier, F., d'Enfert, C. Gymnemic acids inhibit hyphal growth and virulence in Candida albicans. PLoS One 8, e74189 (2013).
43. Kucharikova, S. et al. Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model. Antimicrob Agents Chemother 57, 2365-8 (2013).
44. Mukherjee, P. K., Long, L., Kim, H. G., Ghannoum, M. A. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int J Antimicrob Agents 33, 149-53 (2009).
45. Kuhn, D. M., George, T., Chandra, J., Mukherjee, P. K., Ghannoum, M. A. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46, 1773-80 (2002).
46. Baixench, M. T. et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 59, 1076-83 (2007).
47. Balashov, S. V., Park, S., Perlin, D. S. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 50, 2058-63 (2006).
48. Eschenauer, G., DePestel, D. D., Carver, P. L. Comparison of echinocandin antifungals. Therapeutics and Clinical Risk Management 3, 71-97 (2007).
49. Uppuluri, P., Nett, J., Heitman, J., Andes, D. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 52, 1127-32 (2008).
50. Eddouzi, J. et al. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Antimicrob Agents Chemother 57, 3182-93 (2013).
51. Shah, V. et al. Sophorolipids, microbial glycolipids with anti-human immunodeficiency virus and sperm-immobilizing activities. Antimicrob Agents Chemother 49, 4093-100 (2005).
52. Nett, J. E., Cain, M. T., Crawford, K., Andes, D. R. Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay. J Clin Microbiol 49, 1426-33 (2011).
53. Ramage, G., Vande Walle, K., Wickes, B. L., Lopez-Ribot, J. L. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45, 2475-9 (2001).
54. Dong, J., Signo, K. S., Vanderlinde, E. M., Yost, C. K., Dahms, T. E. Atomic force microscopy of a ctpA mutant in Rhizobium leguminosarum reveals surface defects linking CtpA function to biofilm formation. Microbiology 157, 3049-58 (2011).
55. Ramage, G., Saville, S. P., Wickes, B. L., Lopez-Ribot, J. L. Inhibition of Candida albicans biofilm formation by farnesol, a quorumsensing molecule. Appl Environ Microbiol 68, 5459-63 (2002).
56. Harriott, M. M., Noverr, M. C. Candida albicans and Staphylococcus aureus form polymicrobial biofilms: effects on antimicrobial resistance. Antimicrobial agents and chemotherapy 53, 3914-3922 (2009).
57. Mannan, A.-u., Sharma, S., Ganesan, K. Total RNA isolation from recalcitrant yeast cells. Analytical biochemistry 389, 77-79 (2009).
58. Livak, K. J., Schmittgen, T. D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2CT Method. methods 25, 402-408 (2001).